AbbVie Inc. (ABBV)
| Market Cap | 306.02B |
| Revenue (ttm) | 56.33B |
| Net Income (ttm) | 4.24B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.39 |
| PE Ratio | 72.38 |
| Forward PE | 14.15 |
| Dividend | $6.56 (3.79%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 8,998,007 |
| Open | 173.00 |
| Previous Close | 171.68 |
| Day's Range | 172.07 - 175.07 |
| 52-Week Range | 153.58 - 218.66 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 211.90 (+22.49%) |
| Earnings Date | Apr 25, 2025 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is $211.9, which is an increase of 22.49% from the latest price.
News
My Dividend Stock Portfolio: New All-Time Dividend Record In March - 100 Holdings With 15 Buys
March investments totaled around $1,200, mainly in BDCs like Blue Owl Capital and Ares Capital, boosting annual dividend income by $100. Dividend income hit a new all-time record of $1,404, up 17% Y/Y...
Tariffs on generic drugs will cause companies to stop making them: Former FDA Commissioner Gottlieb
Dr. Scott Gottlieb, former FDA Commissioner, joins 'Squawk Box' to discuss current pharmaceutical imports under investigation, moving production for branded and generic drugs elsewhere, and much more.
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Final Trades: TJX, Meta, Abbvie and Taiwan Semi
The Investment Committee give you their top stocks to watch for the second half.
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
AbbVie Stock Up 9.2% After Key Signal
ALERT COMES AT LOW POINT FOR ABBV AND SIGNALS MAJOR REVERSAL OF OVER 15 POINTS
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade)
AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year-over-ye...
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squ...
Why drug stocks are no longer a safe haven from the stock market's turmoil
Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.
Global pharma shares plunge as Trump doubles down on tariff threat
Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and...
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from the pi...
AbbVie cuts 2025 profit forecast on acquisition expenses
AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition-related expenses.
Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath
Potato maker Lamb Weston Holdings Inc., telecom giant Verizon Communications Inc., drug maker AbbVie Inc. and retailer TJX Cos. all bucked a sharp market selloff Thursday, as Wall Street turned to sto...
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, ...
Best Dividend Aristocrats For April 2025
Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Br...
AbbVie: Margin Expansion Potential Can Support Elevated P/E
I don't see an obvious bias in AbbVie Inc.'s risk/return ratio. But I see it as a solid hold under current conditions. The company is grappling with diminishing Humira sales and is also trading at an ...
AbbVie to Host First-Quarter 2025 Earnings Conference Call
NORTH CHICAGO, Ill. , March 31, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens.